Hi, mooers! 👋
The AI world holds its breath! $NVIDIA (NVDA.US)$ will release its Q4 FY2025 earnings on February 26, just before the market opens.  As the AI kingpin faces heightened scrutiny amid market volatility, will it defy expectations again? This is your chance to earn rewards and gain insights by predicting the opening price. Let’s get into it! 🎉
Stay Ahead of the Game
Subscribe to @Moo Live for real-time updates, expert analysis, and t...

$SES AI Corp (SES.US)$ I will compete with you on 2.24.

$SES AI Corp (SES.US)$ please buy more, this will be diomond in mud, will. Increase soon

$SoundHound AI (SOUN.US)$ just hold. 2040 the price will be 500.

$BigBear.ai Holdings (BBAI.US)$ gap up. trend is your frd

$Exscientia (Delisted) (EXAI.US)$
It’ll only go upwards, target to sell at $35 especially after this press release
Exscientia Announces Closing of $510.4 Million USD
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

$Exscientia (Delisted) (EXAI.US)$ Exscientia surged 23% on its first day of listing, SoftBank is the largest external shareholder
Founded in 2012 and headquartered in Oxford, UK, Exscientia provides an artificial intelligence-driven platform for drug design, discovery and development. The SoftBank Vision Fund is currently its largest external shareholder, accounting for 16.3%.
Exscientia landed on the Nasdaq market on October 1st, opened up 24.09% to $27.30, closed up 23.18% on the day, and had a market value of $3.2 billion. It became the European biotech company with the highest IPO financing amount in the history of the world and the highest market value in the United Kingdom. Biotech company.